Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers

Journal of Occupational and Environmental Medicine

Volumn 49, Issue 10, 2007, Pages 1086-1096

  Sakr, Carine J ^a,b,c   Kreckmann, Kim H ^b   Green, John W ^b   Gillies, Peter J ^b   Reynolds, Julia L ^b   Leonard, Robin C ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUPONT COMPANY   (United States)

^c DuPont Company ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; LIPID; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERFLUOROOCTANOATE AMMONIUM; PERFLUOROOCTANOIC ACID; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HEALTH SURVEY; HUMAN; INDUSTRIAL WORKER; LINEAR REGRESSION ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLISM; NORMAL HUMAN; OCCUPATIONAL EXPOSURE; SCREENING; STATISTICAL SIGNIFICANCE;

EID: 37349120707     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/JOM.0b013e318156eca3     Document Type: Article

References (39)

1. Ubel FA, Sorenson SD, Roach DE. Health status of plant workers exposed to fluorochemicals-a preliminary report. Am Ind Hyg Assoc J. 1980;41:584-589.
2. Olsen GW, Gilliland FD, Burlew MM, Burris JM, Mandel JS, Mandel JH. An epidemiologic investigation of reproductive hormones in men with occupational exposure to perfluorooctanoic acid. J Occup Environ Med. 1998;40:614-622.
3. Olsen GW, Burris JM, Burlew MM, Mandel JH. Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examination. J Occup Environ Med. 2003;45:260-270.
4. Olsen GW, Church TR, Miller JP, et al. Perfluooctanoate and other fluorochemicals in the serum of American Red Cross adult blood donors. Environ Health Perspect. 2003;111:1892-1901.
5. Olsen GW, Church TR, Larson EB, et al. Serum concentrations of perfluorooctanesulfonate and other fluorochemicals in an elderly population from Seattle, Washington. Chemosphere. 2004;54:1559-1611.
6. Olsen GW, Church TR, Hansen KJ, et al. Quantitative evaluation of perfluorooctanesulfonate (PFOS) and other fluorochemicals in the serum of children. J Child Health. 2004;2:53-76.
7. Olsen GW, Huang HY, Helzlsouer KJ, Hansen KJ, Butenhoff JL, Mandel JH. Historical comparison of perfluorooctanesulfonate, perfluorooctanoate, and other fluorochemicals in human blood. Environ Health Perspect. 2005;113:539-545.
8. Kubwabo C, Vais N, Benoit F. A pilot study on the determination of perfluorooctanesulfonate and other perfluorinated compounds in blood of Canadians. J Environ Monit. 2004;6:540-545.
9. Kannan K, Corsolini S, Falandysz J, et al. Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. Environ Sci Technol. 2004;38:4489-4495.
10. Harada K, Saito N, Inoue K, et al. The influence of time, sex and geographic factors on levels of perfluorooctane sulfonate and perfluorooctanoate in human serum over the last 25 years. J Occup Health. 2004;46:141-147.
11. Kuslikis BI, Vanden Heuvel JP, Peterson RE. Lack of evidence for perfluorodecanoyl- or perfluorooctanoyl-coenzyme A formation in male and female rats. J Biochem Toxicol. 1992;7:25-29.
12. Vanden Heuvel JP, Kuslikis BI, Van Rafelghem MJ, Peterson RE. Tissue distribution, metabolism, and elimination of perfluorooctanoic acid in male and female rats. J Biochem Toxicol. 1991;6:83-92.
13. Butenhoff JL, Kennedy GL Jr, Hinderliter PM, et al. Pharmacokinetics of perfluorooctanoate in cynomolgus monkeys. Toxicol Sci. 2004;82:394-406.
14. 14C. Riker Laboratories, Inc., St. Paul, MN. US EPA Administrative Record 226-0457. 1980.
15. Hundley SG, Sarrif AM, Kennedy GL. Absorption, distribution, and excretion of ammonium perfluorooctanoate (APFO) after oral administration to various species. Drug Chem Toxicol. 2006;29:137-145.
16. Haughom B, Spydevold O. The mechanism underlying the hypolipemic effect of perflurooctanoic acid (PFOA), perfluorooctanesulphonic acid (PFOSA), and clofibric acid. Biochim Biophys Acta. 1992;1128:65-72.
17. Pastoor TP, Lee KP, Perri MA, Gillies PJ. Biochemical and morphological studies of ammonium perfluorooctanoate-induced hepatomegaly and peroxisome proliferation. Exp Mol Pathol. 1987;47:98-109.
18. Butenhoff JL, Costa G, Elcombe C, et al. Toxicity of ammonium perfluorooctanoate (APFO) in cynomolgus monkeys after 26 weeks of oral dosing. Toxicol Sci. 2002;69:244-257.
19. Kennedy GL, Butenhoff JL, Olsen GW, et al. The toxicology of perfluorooctanoate. Crit Rev Toxicol. 2004;34:351-384.
20. Han X, Snow T, Kemper R, Jepson G. Binding of perfluorooctanoic acid to rat and human plasma proteins. Chem Res Toxicol. 2003;16:775-781.
21. Burris JM, Olsen G, Simpson C, Mandel J. Determination of serum half-lives of several fluorochemicals. 3M Company. Interim Report # 1. June 8, 2000. US EPA Administrative Record 226-0611.2000.
22. Olsen GW, Burris JM, Ehresman DJ, et al. Half-life of serum elimination of perfluorooctansulfonate, perfluorohexanefulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Pespect. 2007;doi:10.1289/ehp. 10009.
23. Olsen GW, Burris JM, Burlew MM, Mandel JH. Plasma cholecystokinin and hepatic enzymes, cholesterol and lipoproteins in ammonium perfluorooctanoate production workers. Drug Chem Toxicol. 2000;23:603-620.
24. Flaherty JM, Connolly PD, Decker ER, et al. Quantitative determination of perfluorooctanoic acid in serum and plasma by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;819:329-338.
25. Schaefer EJ. Lipoproteins, nutrition, and heart disease. Am J Clin Nutr. 2002;75:191-212.
26. Lyu L-C, Shieh M-J, Posner BM, et al. Relationship between dietary intake, lipoproteins, and apolipoproteins in Taipei and Framingham. Am J Clin Nutr. 1994;60:765-774.
27. Schaefer J, Lamon-Fava S, Ausman LM, et al. Individual variability in lipoprotein cholesterol response to National Cholesterol Education Program Step 2 diets. Am J Clin Nutr. 1997;65:823-830.
28. Castro IA, Barroso LP, Sinnecker P. Functional foods for coronary heart disease risk reduction: a meta-analysis using a multivariate approach. Am J Clin Nutr. 2005;82:32-40.
29. Olsen GW, Zobel LR. Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. Int Arch Occup Environ Health. 2007; DOI 10.1007/s00420-007- 0213-0. [Epub ahead of print].
30. Gilliland FD, Mandel J. Serum perfluorooctanoic acid and hepatic enzymes, lipoproteins, and cholesterol: a study of occupationally exposed men. Am J Ind Med. 1996;29:560-568.
31. DuPont Haskell Laboratory. Liver study of Washington Works employees exposed to C-8: results of blood biochemistry testing. US EPA Administrative Record 226-2761. 1981.
32. Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ. Differential activation of nuclear receptors by normal and perfluorinated fatty acids: a comparison of human, mouse and rat PPAR-α,β-γ, LXR-β and RXR-α. Toxicol Sci. 2005;92:476-489.
33. Murphy EA. Analysis of Variance in Biostatistics in Medicine. The Baltimore: Johns Hopkins University Press; 1982.
34. Diver MJ, Imtiaz KE, Ahmad AM, Vora JP, Fraser WD. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol. 2003;58:710-717.
35. Cook JC, Murray SM, Frame SR, Hurtt ME. Induction of Leydig cell adenomas by ammonium perfluorooctanoate: a possible endocrine-related mechanism. Toxicol Appl Pharmacol. 1992;113:209-217.
36. Biegel LB, Liu RC, Hurtt ME, Cook JC. Effects of ammonium perfluorooctanoate on Leydig cell function: in vitro, in vivo, and ex vivo studies. Toxicol Appl Pharmacol. 1995;134:18-25.
37. Emmett AE, Shofer FS, Zhang H, Freeman D, Desai C, Shaw LM. Community exposure to perfluorooctanoate: Relationships between serum concentrations and exposure sources. J Occup Environ Med. 2006;48:759-770.
38. Emmett AE, Zhang H, Shofer FS, et al. Community exposure to perfluorooctanoate: relationships between serum levels and certain health parameters. J Occup Environ Med. 2006;48:771-779.
39. Sakr CJ, Leonard RC, Kreckmann KH, Slade MD, Cullen MR. Longitudinal study of serum lipids and liver enzymes in workers with occupational exposure to ammonium perfluorooctanoate. J Occup Environ Med. 2007;49:872-879.